Welcome to our dedicated page for Tempest Therapeutics news (Ticker: TPST), a resource for investors and traders seeking the latest updates and insights on Tempest Therapeutics stock.
Tempest Therapeutics, Inc. (NASDAQ: TPST) is a clinical-stage biotechnology company headquartered in Brisbane, California, developing small molecule and cell-based therapeutics with tumor-targeted and immune-mediated mechanisms to fight cancer. The TPST news feed on Stock Titan aggregates company announcements, financial updates, and regulatory milestones that shape the outlook for this oncology-focused biotech.
Investors following TPST news can expect frequent updates on the progress of Tempest’s key programs, including amezalpat (TPST-1120), a selective PPAR⍺ antagonist in development for hepatocellular carcinoma, and TPST-1495, a dual EP2/4 prostaglandin receptor antagonist being advanced for familial adenomatous polyposis. News items often highlight clinical data presentations, regulatory designations from agencies such as the FDA, EMA and China’s NMPA, and clearances or agreements for pivotal or registration-directed trials.
The company also regularly reports quarterly financial results and business updates, detailing research and development spending, cash position, and its ongoing evaluation of strategic alternatives. Capital markets activity, such as registered direct offerings of common stock, private placements of warrants, and shelf registration usage, is disclosed through press releases and corresponding SEC filings and is reflected in the TPST news stream.
In addition, Tempest issues news on strategic transactions, including its agreement to acquire dual-targeting CAR T-cell therapy programs from Factor Bioscience affiliates, which is intended to expand and diversify its clinical-stage pipeline. For market participants tracking TPST, this news page provides a centralized view of clinical, regulatory, financial, and transactional developments. Users interested in Tempest’s evolving oncology pipeline and corporate strategy can review past announcements and monitor new releases as they are published.
Tempest Therapeutics (Nasdaq: TPST), a clinical-stage biotechnology company focused on developing targeted and immune-mediated cancer therapies, announced participation in two investor conferences.
Management will present at TD Cowen's 5th Annual Oncology Innovation Summit on May 29, 2024, at 2:00 p.m. ET and at the Jefferies Global Healthcare Conference on June 5, 2024, at 4:00 p.m. ET.
Recordings of these events will be available on the Tempest investor relations website.
Tempest Therapeutics, Inc. (Nasdaq: TPST) reported financial results for Q1 2024, advancing TPST-1120 and TPST-1495 in clinical trials. TPST-1120 showed positive preclinical and clinical data in kidney and liver cancers. TPST-1495 to enter Phase 2 for FAP. Financially, Tempest ended Q1 with $32.3 million in cash, with net loss of $7.9 million.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.